A canine atopic dermatitis primary prevention study using emollients – A randomised controlled longitudinal study

Financiador

Organização

Publicações

Tackling canine atopic dermatitis : a pilot clinical trial assessing the efficacy of an innovative topical solution

Publication . Mendes, António Silva Carvalho Caldeira

Canine atopic dermatitis (cAD) is a chronic inflammatory skin condition with a multifactorial etiology. In human atopic dermatitis (hAD), treatment focuses on repairing the skin barrier with emollients, while in cAD treatments tend to overlook skin barrier care. New emollient formulations have recently been developed - the "emollients plus". These formulations include bioactive, non-medicated substances with treatment-sparing effects and prolonged free-flare periods in humans. In dogs, evidence for their use is scarce. This pilot study aimed to evaluate the efficacy of a novel biphasic topical emollient plus spray, developed by our research team, as an co-adjuvant therapy for cAD. Twenty-one client-owned dogs diagnosed with non-seasonal chronic cAD were recruited from a veterinary dermatology service. The dogs underwent a 30-day treatment period involving daily application of the topical emollient to body regions commonly affected cAD. Clinical assessments were performed at baseline (D0) and after the treatment period (D30) using validated tools like the Canine Atopic Dermatitis Extent and Severity Index (CADESI-04) and the Pruritus Visual Analog Scale (PVAS10). Skin barrier function and integrity measurements were collected on D0 and D30, including Transepidermal Water Loss (TEWL) and skin pH. On D30, the owner's global assessment of treatment efficacy (OGATE) and cosmetic evaluation were collected. Results indicated a significant reduction in both pruritus and skin lesion severity. PVAS10 scores decreased from 4.25 ± 1.85 at baseline to 3.38 ± 1.75 at D30 (p = 0.02), and CADESI-04 scores decreased from 24.6 ± 18.1 to 13.4 ± 7.4 (p = 0.002). In the pinna, TEWL and pH significantly decreased after 30 days (from 18.63 ± 17.33 to 9.56 ± 10.75 (p = 0.049) and from 6.07 ± 0.97 to 5.41 ± 0.71 (p = 0.01) respectively). Contrarily, in the inguinal region after 30 days, TEWL values increased non-significantly from 13.62 ± 14.59 to 15.32 ± 15.17 (p = 0.75) and pH decreased non-significantly from 6.33 ± 1.24 to 6.12 ± 1.13 (p = 0.54). Notably, 90.48% of owners rated the overall treatment response as "good" or "excellent," and the product was positively evaluated across all cosmetic properties. In conclusion, the novel topical emollient spray showed potential as an effective adjunct therapy for cAD, significantly improving clinical outcomes and yielding high owner satisfaction. However, larger randomized controlled trials must confirm these findings and further explore their impact on skin barrier repair and cAD management

2024-11-25Dissertação de mestrado

Acesso aberto

Ver mais

Entidade financiadora

Fundação para a Ciência e a Tecnologia

Número da atribuição

2021.05985.BD